Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 14, Pages -Publisher
MDPI
DOI: 10.3390/ijms22147350
Keywords
epigenetics; DNA methylation; microRNAs; cancer; biomarkers; clinical applications
Funding
- Instituto de Salud Carlos III [PI19/00572]
- European Regional Development Fund, Away to make Europe
- Valorizacion y Transferencia a las empresas, de la Agencia Valenciana de la Innovacion [INNVA1/2020/71]
Ask authors/readers for more resources
Cancer is a complex disease involving alterations in multiple processes, with genetic and epigenetic features as core factors. Non-coding RNAs (ncRNAs), particularly microRNAs, play a key role in cancer initiation and progression by controlling cellular processes like proliferation, differentiation, and apoptosis. The expression of microRNAs is regulated by other epigenetic factors, resulting in aberrant expression patterns in cancer, and evaluating aberrant microRNA landscape holds promise for cancer management.
Cancer is a complex disease involving alterations of multiple processes, with both genetic and epigenetic features contributing as core factors to the disease. In recent years, it has become evident that non-coding RNAs (ncRNAs), an epigenetic factor, play a key role in the initiation and progression of cancer. MicroRNAs, the most studied non-coding RNAs subtype, are key controllers in a myriad of cellular processes, including proliferation, differentiation, and apoptosis. Furthermore, the expression of miRNAs is controlled, concomitantly, by other epigenetic factors, such as DNA methylation and histone modifications, resulting in aberrant patterns of expression upon the occurrence of cancer. In this sense, aberrant miRNA landscape evaluation has emerged as a promising strategy for cancer management. In this review, we have focused on the regulation (biogenesis, processing, and dysregulation) of miRNAs and their role as modulators of the epigenetic machinery. We have also highlighted their potential clinical value, such as validated diagnostic and prognostic biomarkers, and their relevant role as chromatin modifiers in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available